Polynovo has two operating businesses, being PolyNovo Biomaterials Pty Ltd (PolyNovo) and Metabolic Pharmaceuticals Pty Ltd (Metabolic). PolyNovo is focused on developing its biodegradable polymer platform technology NovoSorb for medical products targeting reconstructive surgery and tissue repair. Metabolic owns the intellectual property around AOD9604 which is in development for the treatment of obesity, bone, cartilage and muscle diseases and repair.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.